✦ LIBER ✦

Leukocyte response to thymoglobulin or Atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients

✍ Scribed by D.C Brennan; K Flavin; J.A Lowell; T.K Howard; S Shenoy; S Burgess; S Dolan; J.M Kano; M Mahon; M.A Schnitzler; R Woodward; W Irish; V Ramachamdra; G.G Singer

Book ID: 117238009
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 119 KB
Volume: 31
Category: Article
ISSN: 0041-1345
DOI: 10.1016/s0041-1345(99)00096-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Switch to a Sirolimus-Based Immunosuppre

Switch to a Sirolimus-Based Immunosuppression in Long-Term Renal Transplant Recipients: Reduced Rate of (Pre-)Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor-Blinded, Controlled Clinical Trial

✍ R. Salgo; J. Gossmann; H. Schöfer; H. G. Kachel; J. Kuck; H. Geiger; R. Kaufmann 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB